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Background: Guidelines from the NMDP and ASBMT
recommend allogeneic donor mobilization with 4-5 days of
G-CSF followed by peripheral blood stem cell (PBSC) collec-
tion beginning the 5th day. While our institutional standard
has been 5-day mobilization and collection, given observa-
tions that some autologous transplant patients are
adequately mobilized by day 4, and due to concern that a
subset of allogeneic donors may be maximally mobilized
earlier than day 5, we performed a feasibility study evalu-
ating day 4 collection of allogeneic PBSC.
Methods: Beginning 7/1/2013, HLA-matched sibling donors
were collected on day 4 after G-CSF if the peripheral blood
(PB) CD34 count was 0.04x106/ml. Collected PBSC were
held overnight at 4⁰C until transplant. Donors with day 4 PB
CD34 counts of 0.04x106/ml were collected on day 5, and
those with inadequate CD34 cells/kg recipient weight in the
PBSC product underwent repeat collection over two days.
Results: 38 patients with matched-sibling donors were
eligible for inclusion in the study, with a median follow-up of
217 days (range 45-458). Of 38 donors evaluated, 22 (57.9%)
had a PB CD34 count 0.04x106/ml on day 4. Eighteen of the
22 (81.8%) were adequately collected on day 4; 3 required 2-
day PBSC collections on days 4 and 5. One donor with an
adequate PB CD34 count was collected on day 5 due to line
issues. Of the 16 donors with a PB CD34 count <0.04x106/ml,
7 underwent single day collection on day 5, and 9 required
two-day collections. Of all donors eligible for inclusion, 18
(47.4%) were adequately collected on day 4, 8 (21.1%) were
collected on day 5, and 31.6% required two-day collections.
There was no signiﬁcant difference in the median time to
ANC and platelet engraftment based on day of PBSC
collection.
Conclusions: In our pilot study of HLA-matched sibling do-
nors undergoing G-CSF mobilized PBSC collection, we found
that 47.4% of donors were adequatelymobilized to allow for a
single PBSC collection on day 4. Using a PB CD34 cell
threshold of 0.04x106/ml on day 4 identiﬁed donors withMedian Day 4 n¼18 Day 5 n¼8 Two-Days
n¼12
Donor/Recipient age (years) 51/51 51.5/51 56/58
Donor/Recipient weight (kg) 87.1/86.5 75.5/79.0 83.5/94.5
Day 4 PB CD343106/mL 0.07 0.028 0.024
PB CD343l06/mL at collection n/a 0.057 0.038
PBSC CD343l06/kg 7.43 5.38 2.72
TNC3108/kg 6.99 8.24 12.0
MNC3108/kg 5.84 7.51 10.7
CD33l08/kg 2.17 2.52 3.92
Day ANC >500/ml 13 14 15
Day platelets >203l09/L 17.5 17.5 18high likelihood of adequate PBSC collection (81.8%). Our
preliminary data suggest day 4 may be the optimal day of
collection for a population of healthy donors, reducing donor
G-CSF exposure leading to enhanced safety for donor and
recipient, and expected cost savings. Ongoing analyses
include ﬁnancial and resource utilization review, detailed
comparison of day 4 versus 5 PBSC product composition, and
matched cohort analysis of day 4 versus 5 collection and
correlation with transplant outcomes.432
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Background: Placental growth factor (PlGF) is a member of
the vascular endothelial growth factor (VEGF) family, with a
role in inﬂammation and monocyte chemotaxis. Pathologi-
cally high levels of PlGF have been described in the setting of
inﬂammatory diseases, and upregulation of the PlGF receptor
(VEGFR1) can be induced by vascular injury and inﬂamma-
tion. In a pilot study, we identiﬁed that circulating levels of
PlGF are signiﬁcantly elevated in recipients of allogeneic HCT.
Thus, we hypothesized that PlGF may play an immuno-
modulatory role post-HCT, and sought to quantify differ-
ences in circulating PlGF levels between HCT donors and
recipients, characterize peripheral blood mononuclear cell
(PBMC) expression of VEGFR1, and determine GVHD target
organ expression of PlGF.
Patients and Methods: Plasma and PBMCs from a cohort of
14 adult patients undergoing allogeneic HCT were collected
at 3 months post-HCT and compared to samples obtained
from their matched sibling donors (MSD). Plasma PlGF levels
were quantiﬁed by ELISA; PBMC expression of VEGFR1 was
determined by ﬂow cytometry. Immunohistochemical (IHC)
staining for PlGF was performed on biopsies of aGVHD target
organs.
Results: PlGF levels and VEGFR1 expression: PlGF levels
were 3.5-fold higher (25.1 versus 7.1 pg/mL, p¼0.006) in
recipients at 3 months post-HCT compared to their MSD and
negatively associated with steroid dose (r¼-0.6, p¼0.02).
Allogeneic HCT recipients had signiﬁcantly higher levels of
circulating monocytes (15.4 vs 8.1%, p¼0.05) and approxi-
mately double the percentage of both CD8+ T-cell (1.5 vs 0.6%,
p¼0.009) and CD3-CD11b+DR(lo) myeloid-derived suppres-
sor cell (6.0 vs 3.3%, p¼0.01) subsets expressing VEGFR1,
compared to MSDs. PlGF tissue expression: Seven of 9 skin
biopsies were consistent with aGVHD by pathology review.
PlGF was present at 2-3+ staining intensity in all 7 cases of
skin aGVHD, while the 2 cases without aGVHD, as well as
normal skin, had little to no PlGF staining (0-1+). In contrast,
control GI tissues showed higher PlGF staining (2-3+). Four-
teen of 15 GI biopsies were consistent with aGVHD. PlGF
expression in patients with GI aGVHD was less intense than
control GI biopsies in 11/15 cases, with lowest scores
observed in two patients who died of steroid refractory GI
aGVHD.
Conclusion: Elevated PlGF in HCT recipients is associated
with an increase in monocytes and VEGFR1-expressing
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tionally, increased tissue expression of PlGF by IHC was seen
in skin biopsies of aGVHD, while GI aGVHD tissue demon-
strated pathologically low PlGF expression. To our knowl-
edge, these results provide the ﬁrst evidence of altered
circulating and tissue expression of PlGF occurring in the HCT
setting. Studies are ongoing to determine the role of PlGF in
neovascularization and tissue repair in aGVHD, and on the
direct angiogenic and immune regulatory effect of PlGF in
HCT.433
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Umbilical cord blood (UCB) is an alternative option for he-
matopoietic stem cell transplantation and it has been suc-
cessfully used to treat children with malignant and non
malignant diseases. The slower rate of neutrophil engraft-
ment and delayed immune reconstitution impose a sub-
stantial risk for infections and mortality. Furthermore, the
use of anti-thymocyte globulin (ATG) has been linked to a
higher risk of viral infections. In order to assess the occur-
rence of viral infections we retrospectively analyzed the
outcomes of 156 children who underwent a UCB transplant
(UCBT) between January 1996 and October 2012 in a single
institution. Diagnostic methods varied over time: initially
antigenemia, immunoﬂuorescence and immunoenzymatic
tests were used and since 2005 Polymerase Chain Reaction
(PCR) was employed for vigilance and diagnosis of viral
reactivation. Fifty-one girls and 105 boys with a median age
of 60 months (range 2 e 168 months) were transplanted for
malignant (48 pts) and non-malignant diseases: BM failure
syndromes: 55 patients (pts), primary immunodeﬁciencies
(PID): 41 pts and inborn errors of metabolism (IEM): 12 pts.
HLA compatibility: 6/6 or 5/6: 98 pts and 4/6: 58 pts. Con-
ditioning Regimen was based on chemotherapy in 119 pts
and TBI based in 37 pts. The median number of Total
Nucleated Cell was 5.2 x 107/Kg (range: 1.4 - 36.4 x 107/Kg).
One hundred and forty-three pts were evaluable for
engraftment with a median time for neutrophil recovery of
26 days and for platelet recovery of 42 days. Viral infection
occurred in 99/156 pts. In the univariate analysis it was more
frequent in pts who received ATG: 87/122 (p 0.0001), in
those who developed acute GVHD: 65/80 (p 0.0001) or
chronic GVHD: 49/59 (p 0.0001) and in 4/6 HLA mismatched
UCBT (p 0.001). The most frequent virus detected in this
cohort was Cytomegalovirus (CMV): 74 pts, followed by
Epstein-Barr virus (EBV): 14 pts and adenovirus: 8pts. CMV
status pre-transplant correlated with higher incidence of
CMV infection post transplant. Moreover, viral infections
were associated with bacterial infection in 79/127 pts
(p 0.01). Death occurred in 81 pts and the main cause wasbacterial infection. In this analysis the presence of viral
infection per se was not associated with a high mortality.
Conclusion: We observed a high prevalence of viral in-
fections among UCB recipients and a positive association of
its occurrence with HLA-mismatch, development of acute or
chronic GVHD and the use of ATG. Viral infections were
usually associated with other infectious agents such bacteria
or fungi and this could be an important factor for morbidity
and mortality. Currently, close PCR surveillance allows early
detection of viremia and aggressive treatment.434
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Background: CMV recipient seropositivity (R+) is a predictor
for CMV viremia after SCT. Cytotoxic T-lymphocytes (CTL) are
critical for CMV immunity. Conventional allografts from CMV
seropositive donors (D+) confer some CMV immunity though
transfer of donor CTLs to the recipient. Thus for CMV R+, CMV
D+ are preferentially chosen over CMV D-. In contrast, ex-
vivo T-cell depleted (TCD) allografts are deﬁcient in CMV
CTLs. The effect of donor serostatus on CMV reactivation has
not been examined after TCD SCT. We studied the effect of
CMV donor serostatus on the incidence of CMV viremia in a
cohort of adult CMV R+, TCD SCT monitored by CMV PCR and
treated preemptively.
Methods: CMV R+ adults with hematologic malignancies
who received peripheral blood CD34+ selected allografts
after myeloablative conditioning regimens from March 1,
2010 through May 2013 were monitored prospectively by
CMV PCR at least weekly from day (d) +14 through +100 and
at least once every 2 weeks through d +180. Preemptive
therapy was initiated for CMV viremia, deﬁned as  1 posi-
tive PCR value. There was no CMV prophylaxis during the
study period. Follow up was through May 31, 2014. Time-
dependent Cox-proportional hazard model of univariate and
multivariate stepwise selection analyses were performed to
identify predictors of CMV viremia.
Results: Of 113 CMV R+ (median age 57.6 years, 22.5-73.0),
60 (53%) had acute leukemia, 23 (20%) myelodysplastic
syndrome, 18 (16%) multiple myeloma and 12 (11%) other.
Donors were 48 (42%) matched-related (MRD), 45 (40%)
matched unrelated (MUD), or 20 (18%)mismatched; 68 (60%)
CMV D+ or 45 (40%) D-. The cumulative incidence of CMV
viremia at 6 months was 79%. Time to onset of viremia was
median 26 days (13-83) after SCT, and time to resolution of
viremia a median 30.5 days from onset of viremia. The inci-
dence of CMV viremia was higher in R+/D+ compared to R+/
D- (90.5% versus 62.2%; P<0.0001). Median time to onset and
to resolution for R+/D+ vs R+/D- were not signiﬁcantly
different. In multivariable analysis, R+/D- pts were at lower
risk for CMV viremia compared to R+/D+ (HR: 0.57, 95% CI:
0.36-0.90; P¼0.017). In contrast, multiple myeloma (HR:
2.22, 95% CI: 1.24-3.98; P¼0.008) was associated with
increased risk compared with acute leukemia. Having a
mismatched donor was also associated with increased risk
